IsisCB Explore

Article ID: CBB976475287

Global Diversification in Medicine Regulation: Insights from Regenerative Stem Cell Medicine (2019)

Rosemann, Achim (Author)
Vasen, Federico (Author)
Bortz, Gabriela (Author)

Science as Culture
Volume: 28
Issue: 2
Pages: 223-249

DOI: 10.1080/09505431.2018.1556253

URI: https://doi.org/10.1080/09505431.2018.1556253

Outside Links

PubMed

WorldCat

Google Scholar

JSTOR

Academia.edu

Medicine regulation worldwide has undergone a process of regulatory diversification. The evidence-based medicine (EBM) paradigm, centered on multi-phase randomized controlled trials, is increasingly contested and replaced by new models of clinical validation. To explain these changes, STS research has cited just a few factors, e.g. growing pressure form health consumers; the role of pharmaceutical companies to lobby for fast, affordable drug development; the influence of neoliberal ideas and libertarian advocacy of deregulation; and the agency of national governments to enable domestic innovation opportunities in the context of global competition and inequalities. Those factors individually cannot account for the increasing variation in medicine regulation at both national and global levels. Instead it is helpful to integrate elements of existing explanations into a framework with four pairs of conflicting regulatory choices, which play a central role in the formation of medicine regulation. We use this framework to compare regulatory changes in the USA, European Union, China, India, Argentina, and Japan. Across these jurisdictions, the case studies illustrate four dynamics of diversification. Key regulatory concepts such as evidence, risk, safety, efficacy, responsibility and accountability acquire different meanings, reshaping medicine innovation in far-reaching and often contradictory ways. The boundaries between medical research and healthcare provision, commerce and humanitarian service, as well as state control and medical self-regulation are re-defined.

...More

Included in

Article Achim Rosemann (2019) Alter-Standardizing Clinical Trials: The Gold Standard in the Crossfire. Science as Culture (pp. 125-148). unapi

Citation URI

https://data.isiscb.org/isis/citation/CBB976475287/

Citations Indexes

Similar Citations

Article Sonja Erikainen; Anna Couturier; Sarah Chan; (2020)
Marketing Experimental Stem Cell Therapies in the UK: Biomedical Lifestyle Products and the Promise of Regenerative Medicine in the Digital Era (/isis/citation/CBB771315477/)

Article Christine Hauskeller; Nicole Baur; Jean Harrington; (2019)
Standards, Harmonization and Cultural Differences: Examining the Implementation of a European Stem Cell Clinical Trial (/isis/citation/CBB953736485/)

Article Stephens, Neil; Atkinson, Paul; Glasner, Peter; (December 2011)
Documenting the doable and doing the documented: Bridging strategies at the UK Stem Cell Bank (/isis/citation/CBB128580755/)

Article Koichi Mikami; (2015)
State-Supported Science and Imaginary Lock-in: The Case of Regenerative Medicine in Japan (/isis/citation/CBB782339019/)

Article Margaret Sleeboom-Faulkner; (June 2019)
Regulatory brokerage: Competitive advantage and regulation in the field of regenerative medicine (/isis/citation/CBB470996355/)

Book Broadbent, Alex; (2013)
Philosophy of Epidemiology (/isis/citation/CBB001420137/)

Article Kushner, Howard I.; (2007)
The Other War on Drugs: The Pharmaceutical Industry, Evidence-Based Medicine, and Clinical Practice (/isis/citation/CBB001232010/)

Chapter Lorenzo Beltrame; (2015)
Cellule e ordine sociale: il dibattito italiano sulle cellule staminali (/isis/citation/CBB813029159/)

Article Arthur Daemmrich; (2019)
Welcoming (Newbie) Scholars to the Field (/isis/citation/CBB904595256/)

Article John Gardner; (September 2017)
Accelerating Innovation in the Creation of Biovalue: The Cell and Gene Therapy Catapult (/isis/citation/CBB000462445/)

Article Michael Fisch; (January 2018)
Regenerating Bodies (/isis/citation/CBB804390474/)

Article Bronwyn Parry; (January 2018)
The Social Life of “Scaffolds” Examining Human Rights in Regenerative Medicine (/isis/citation/CBB220784562/)

Article Alex Faulkner; (2019)
Special Treatment? Flexibilities in the Politics of Regenerative Medicine’s Gatekeeping Regimes in the UK (/isis/citation/CBB938616624/)

Article Morten Sager; Teun Zuiderent-Jerak; (May 2021)
Knowing Times: Temporalities of Evidence for Implantable Cardioverter Defibrillators (/isis/citation/CBB852337010/)

Article November, Joseph A.; (2011)
Early Biomedical Computing and the Roots of Evidence-Based Medicine (/isis/citation/CBB001231715/)

Book Abigail A. Dumes; (1920)
Divided Bodies: Lyme Disease, Contested Illness, and Evidence-Based Medicine (/isis/citation/CBB687864939/)

Article Saana Jukola; (2017)
On ideals of objectivity, judgments, and bias in medical research – A comment on Stegenga (/isis/citation/CBB309655322/)

Article Canguilhem, Georges; (1987)
La décadence de l'idée de progrès (/isis/citation/CBB000056461/)

Book Colleen Derkatch; (2016)
Bounding Biomedicine: Evidence and Rhetoric in the New Science of Alternative Medicine (/isis/citation/CBB739944455/)

Article Antoine Lentacker; (2016)
The Symbolic Economy of Drugs (/isis/citation/CBB275575609/)

Comments

{{ comment.created_by.username }} on {{ comment.created_on | date:'medium' }}